Endocrine Abstracts

Mitotane (MTT) currently represents the treatment of choice for adrenocortical carcinoma (ACC). Clinical evidence shows the occurrence of hypogonadism following treatment with this drug, observed more frequently in male patients. The aim of the study, therefore, was to evaluate the impact of MTT treatment on male gonadal function on adult CD1 mice. At the end of the 45 days of treatment, testes were collected for morphological examination, and a blood sample of each animal was...